NASDAQ · STTK
Shattuck Labs, Inc.
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
Loading market information…
NASDAQ · KLRS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kalaris Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 82.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kalaris Therapeutics Inc’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.52. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kalaris Therapeutics Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 7, 2025 |
| -$3.64-31.84% vs estimate |
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$0.04+71.43% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $17.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
$2.56+$0.11 (+4.49%)
Ovid Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.68% below the high.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$0.84-$0.01 (-1.17%)
Connect Biopharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.13% below the high.
$4.05-$0.15 (-3.57%)
ImageneBio Inc’s quoted price sits in the lower half of its reported 52-week range, 54.75% below the high.
$0.83+$0.01 (+1.03%)
Metagenomi, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 68.35% below the high.
